Stay updated on SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial

Sign up to get notified when there's something new on the SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    A banner announces NIH website transition updates and says federal agencies are using “Super Intelligence” in place of “Artificial Intelligence” during the transition.
    Difference
    0.3%
    Check dated 2026-10-25T02:02:26.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    The site footer revision changes from v3.7.1 to v3.7.2.
    Difference
    0.0%
    Check dated 2026-10-18T01:52:55.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer now identifies the site as revision v3.7.1 instead of v3.7.0.
    Difference
    0.0%
    Check dated 2026-10-11T02:20:52.000Z thumbnail image
  4. Check
    37 days ago
    Change Detected
    Summary
    The history now shows a new revision entry labeled v3.7.0. The previous entry v3.6.6 has been removed.
    Difference
    0.0%
    Check dated 2026-09-20T00:58:10.000Z thumbnail image
  5. Check
    58 days ago
    Change Detected
    Summary
    The page's revision label updates from v3.6.5 to v3.6.6. This represents a software version update and does not modify the study history data shown.
    Difference
    0.0%
    Check dated 2026-08-29T21:59:48.000Z thumbnail image
  6. Check
    79 days ago
    Change Detected
    Summary
    A new revision entry v3.6.5 is added to the history, representing the latest platform update. The previous revision v3.6.4 is removed from the history listing.
    Difference
    0.0%
    Check dated 2026-08-08T17:41:45.000Z thumbnail image

Stay in the know with updates to SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial page.